“We’re not trying to be everything for everyone. Our specialized focus has been very exciting for me.” Franco Negron, CEO of Simtra BioPharma Solutions, has transformed a 65-year sterile manufacturing legacy into an independent CDMO since the company’s carve-out from
Carole Delauney warns that sterile injectable manufacturing “is not just fill-finish”—a misconception that can cost biotech companies millions and even derail entire drug development programs. She notes, “This is unfortunately not commonly recognized in the industry, but it is a
The pharmaceutical industry is witnessing unprecedented demand for sterile injectable products, particularly those with complex formulations and specialized delivery requirements. As molecules become more sophisticated and viscosities climb, the need for CDMOs with deep technical expertise and flexible capabilities has
